ICON PLC
NASDAQ:ICLR
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
126.62
203.07
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IE |
|
ICON PLC
NASDAQ:ICLR
|
14.2B USD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.3T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
241B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
170.9B USD |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
38.3B CHF |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
41B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
279.2B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
39.6B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
46.3T KRW |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
29.5B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
23.7B USD |
Loading...
|
Market Distribution
| Min | -5 292.3% |
| 30th Percentile | 0.1% |
| Median | 9.5% |
| 70th Percentile | 13.7% |
| Max | 178.8% |
Other Profitability Ratios
ICON PLC
Glance View
In the rapidly evolving landscape of global healthcare, ICON PLC stands out as a formidable player, seamlessly bridging the gap between innovative drug development and practical clinical application. Founded in Dublin, Ireland, ICON has grown into a multinational enterprise, deeply embedded in the research and development phases of various medical and biopharmaceutical companies. The company's core strength lies in its ability to offer comprehensive clinical trial services, encompassing every stage of drug development, from initial study design through to final data management and regulatory submissions. ICON's systematic approach not only shortens the timeline for bringing novel therapeutics to market but also ensures that these breakthroughs are both effective and safe, thereby garnering trust from clients ranging from burgeoning biotech startups to pharmaceutical giants. As a contract research organization (CRO), ICON operates within a business model designed to capitalize on the booming demand for outsourced R&D support. This model involves entering into strategic partnerships with clients to conduct all necessary research activities in exchange for fees, which can be structured through agreements for specific projects or longer-term collaborations. The company leverages its robust network, sophisticated technological platforms, and expert workforce to offer tailored solutions that optimize efficiency and accuracy. By doing so, ICON not only enhances its clients’ product pipelines but also secures a steady stream of revenue, further consolidated through repeat business and the expansion of its service repertoire to include emerging areas like digital health and real-world evidence. This disciplined and innovative approach propels ICON's growth, ensuring its financial health and reaffirming its integral role in driving medical advancement worldwide.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for ICON PLC is 14%, which is above its 3-year median of 13.2%.
Over the last 3 years, ICON PLC’s Operating Margin has increased from 10.9% to 14%. During this period, it reached a low of 10.9% on Sep 30, 2022 and a high of 14.7% on Dec 31, 2024.